2.03 USD
▲-0.05+3.57%
盘后 1.99 +1.53%
2026-08-03
市值
$5.82M
市盈率
—
EPS
-5.57
股息率
—
52 周区间
1.86 – 14.64
成交量
40.67K
Beta
1.89
目标价
16.67
52W 低 1.8652W 高 14.64
价格走势
公司简介
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatm...